The global Anti-Obesity Prescription market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Obesity is a public health problem. Obesity is a genetic and chronic metabolic disease involving accumulation of excessive or abnormal fat in the body. It contributes to risk of chronic conditions such as cancer, hypertension, cardiovascular diseases, diabetics, obstructive sleep apnea, ventilatory failure, renal failure and asthma. According to a World Health Organization (WHO) report published in 2014, around 3.4 million adults in the world die each year due to obesity related issues. Increasing prevalence of obesity among children and adults is posing a threat and developing nations. Effective intervention strategies such as increased physical activity, behavioral and dietary changes are commonly used to control and prevent obesity. Obesity has a major impact on population longevity and health related expense.

According to our Wellness & Health Research Center, the global wellness & health economy was valued at US dollars 4.8 trillion. Asia Pacific was the region with the highest spending on big health in 2022, with a total spending of $1.68 trillion, followed by North America ($1.42 trillion) and Europe ($1.0 trillion). According to the health industry accounting analysis data disclosed by the Health Development Research Center of the National Health Commission, from 2019 to 2021, the market size of the health service industry grew by an average of 7.0% per year, and the specific data increased from 7.7 trillion yuan to 8.8 trillion yuan. Chinas health industry revenue reached 8.0 trillion yuan in 2021, with an increase of 8.1%. According to public information, in 2022, there were about 1.2 billion obesity cases worldwide, among them, the number of obesity cases in China reached 230 million. Wellness & Health Research Center, the global sports economy was valued at 750 billion in 2022, 92% of global spending on physical activity occurs in Asia Pacific, North America and Europe. And China and the United States accounted for 44% of total sports spending.

Infinity Market Research newest research report, the Anti-Obesity Prescription Industry Forecast looks at past sales and reviews total world Anti-Obesity Prescription sales in 2024, providing a comprehensive analysis by region and market sector of projected Anti-Obesity Prescription sales for 2025 through 2031. With Anti-Obesity Prescription sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-Obesity Prescription industry.

This Insight Report provides a comprehensive analysis of the global Anti-Obesity Prescription landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-Obesity Prescription portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Anti-Obesity Prescription market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-Obesity Prescription and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-Obesity Prescription.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Obesity Prescription market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Bupropion and Naltrexone
    Orlistat
    Lorcaserin
    Phentermine and Topiramate
    Liraglutide

Segmentation by Application:

    Hospital Pharmacies
    Retail Pharmacies
    E-Commerce

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Zydus Cadila
    Akrimax Pharmaceuticals
    Zealand Pharma
    Arrowhead Research
    Arena Pharmaceuticals
    Compellis Pharmaceuticals
    Yungjin Pharm
    Alpex Pharma
    Bridge BioResearch

Key Questions Addressed in this Report

What is the 10-year outlook for the global Anti-Obesity Prescription market?
What factors are driving Anti-Obesity Prescription market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-Obesity Prescription market opportunities vary by end market size?
How does Anti-Obesity Prescription break out by Type, by Application?